LIFR and myeloid sarcoma: Our results highlight proteins of potential mechanistic importance that could serve as potential biomarker candidates for MS amelioration (PD-L1, LIF-R, TGF-β1, and CCL28) or worsening (TRANCE, TWEAK, CCL8, CCL13, and CXCL5).